Payment overview · 2025
General Payments
$5,915.68
140 reported records · 49 companies
Healthcare provider profile · identity verified
Mohammad Mobayed, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · ROCHESTER HILLS, MI · NPI 1114134632
Verified facts
What the public records show
CMS Open Payments records show Mohammad Mobayed, MD received $5,915.68 in general payments during 2025 across 140 reported records.
AstraZeneca Pharmaceuticals LP accounted for 48.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 73 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Braftovi, Mektovi, Xtandi.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRAFTOVI as an associated drug or biological on 11961 records involving 4943 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Braftovi by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MEKTOVI as an associated drug or biological on 10290 records involving 4599 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mektovi by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xtandi by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRAFTOVI as an associated drug or biological on 627 records involving 419 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Braftovi by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MEKTOVI as an associated drug or biological on 200 records involving 184 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mektovi by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $2,880.21 | 48.7% | 9 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $288.57 | 4.9% | 13 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $255.25 | 4.3% | 12 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $209.12 | 3.5% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $146.93 | 2.5% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $111.87 | 1.9% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $104.92 | 1.8% | 4 | 2025 |
| ACCORD HEALTHCARE, INC. | Unresolved — no canonical attribution shown | $98.57 | 1.7% | 3 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $97.23 | 1.6% | 4 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $82.33 | 1.4% | 4 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $78.89 | 1.3% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $76.49 | 1.3% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $71.71 | 1.2% | 3 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.47 | 1.2% | 4 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $62.68 | 1.1% | 3 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $62.10 | 1.1% | 3 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $62.09 | 1.1% | 3 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.78 | 1.0% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $59.72 | 1.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.98 | 0.9% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $55.43 | 0.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.60 | 0.9% | 3 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $52.86 | 0.9% | 2 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $51.93 | 0.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $49.91 | 0.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.42 | 0.8% | 2 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $44.95 | 0.8% | 2 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $44.06 | 0.7% | 1 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.21 | 0.7% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.12 | 0.7% | 2 | 2025 |
| Spectrum Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.78 | 0.7% | 2 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.06 | 0.6% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $33.90 | 0.6% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $31.77 | 0.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.63 | 0.5% | 1 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.23 | 0.5% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.12 | 0.5% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $27.56 | 0.5% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $26.51 | 0.5% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $25.66 | 0.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.16 | 0.4% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $23.21 | 0.4% | 1 | 2025 |
| Coherus Oncology, Inc. | Unresolved — no canonical attribution shown | $22.97 | 0.4% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.52 | 0.3% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $20.50 | 0.3% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $20.07 | 0.3% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $18.67 | 0.3% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $18.55 | 0.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.41 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,215.68 | 138 |
| Consulting Fee | $2,680.00 | 1 |
| Education | $20.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $143.87 | 6 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $115.32 | 5 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $104.92 | 4 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $99.14 | 4 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $97.23 | 4 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological, Drug | Janssen Biotech, Inc., Legend Biotech USA Inc. | $97.08 | 4 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $96.97 | 4 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $91.39 | 5 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $89.81 | 4 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $75.87 | 3 | 2025 |
Source payment records
|
|||||
| Camcevi Normalized: camcevi |
Drug | ACCORD HEALTHCARE, INC. | $73.49 | 2 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $71.24 | 3 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $69.47 | 4 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $68.44 | 3 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $62.68 | 3 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $62.68 | 3 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $62.10 | 3 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $62.09 | 3 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $59.72 | 3 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $57.16 | 2 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $55.43 | 2 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $52.86 | 2 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $52.23 | 3 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $52.23 | 3 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $49.94 | 2 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $49.91 | 2 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $48.40 | 2 | 2025 |
Source payment records
|
|||||
| Xtandi Normalized: xtandi |
Drug | Astellas Pharma US Inc | $47.42 | 2 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $47.08 | 2 | 2025 |
Source payment records
|
|||||
| Tecentriq Hybreza Normalized: tecentriq hybreza |
Biological | Genentech USA, Inc. | $45.35 | 2 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $44.95 | 2 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $44.06 | 1 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $42.21 | 2 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $42.21 | 2 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $42.21 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $42.12 | 2 | 2025 |
Source payment records
|
|||||
| ROLVEDON Normalized: rolvedon |
Drug | Spectrum Pharmaceuticals Inc. | $38.78 | 2 | 2025 |
Source payment records
|
|||||
| VIVIMUSTA Normalized: vivimusta |
Drug | Azurity Pharmaceuticals, Inc. | $37.81 | 2 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $34.81 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $33.90 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $31.77 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $30.63 | 1 | 2025 |
Source payment records
|
|||||
| Columvi Normalized: columvi |
Biological | Genentech USA, Inc. | $30.37 | 1 | 2025 |
Source payment records
|
|||||
| Lunsumio Normalized: lunsumio |
Biological | Genentech USA, Inc. | $30.37 | 1 | 2025 |
Source payment records
|
|||||
| Empaveli Normalized: empaveli |
Drug | Apellis Pharmaceuticals, Inc. | $30.23 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $30.12 | 1 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $27.80 | 1 | 2025 |
Source payment records
|
|||||
| Phesgo Normalized: phesgo |
Biological | Genentech USA, Inc. | $27.80 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $26.90 | 3 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $26.51 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $25.34 | 1 | 2025 |
Source payment records
|
|||||
| Hercessi Normalized: hercessi |
Drug | ACCORD HEALTHCARE, INC. | $25.08 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| LOQTORZI Normalized: loqtorzi |
Biological | Coherus Oncology, Inc. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| ALYMSYS Normalized: alymsys |
Drug | Amneal Pharmaceuticals LLC | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| Tibsovo Normalized: tibsovo |
Drug | SERVIER PHARMACEUTICALS LLC | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| POTELIGEO Normalized: poteligeo |
Drug | KYOWA KIRIN, INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| NIKTIMVO Normalized: niktimvo |
Drug | Incyte Corporation | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $15.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRAFTOVI braftovi |
2025 | Braftovi | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MEKTOVI mektovi |
2025 | Mektovi | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Xtandi xtandi |
2025 | Xtandi | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | BRAFTOVI open payments reported associated product |
CMS Open Payments — General Payments 11961 supporting records · 4943 recipient NPIs · example record 1228794645 |
Braftovi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | MEKTOVI open payments reported associated product |
CMS Open Payments — General Payments 10290 supporting records · 4599 recipient NPIs · example record 1228794645 |
Mektovi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 22 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | BRAFTOVI open payments reported associated product |
CMS Open Payments — General Payments 627 supporting records · 419 recipient NPIs · example record 1228794592 |
Braftovi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | MEKTOVI open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 184 recipient NPIs · example record 1228805516 |
Mektovi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 66 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | 32 |
| Hydroxyurea | Hydroxyurea | 51 | 16 |
| Ondansetron Odt | Ondansetron | 34 | 27 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 32 | 27 |
| Dexamethasone | Dexamethasone | 28 | 18 |
| Prednisone | Prednisone | 27 | 18 |
| Acyclovir | Acyclovir | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Braftovi | Encorafenib | 22 | suppressed |
| Mektovi | Binimetinib | 22 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 16 |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Exemestane | Exemestane | 17 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Gabapentin | Gabapentin | 14 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Xtandi | Enzalutamide | 13 | suppressed |
| Furosemide | Furosemide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,915.68 · 140 records | AstraZeneca Pharmaceuticals LP | AKEEGA, ALYMSYS, Amtagvi, BALVERSA, BESREMI, BLENREP, BRAFTOVI, BRUKINSA, CABOMETYX, CALQUENCE, CARVYKTI, Camcevi, Columvi, DANZITEN, DARZALEX, DATROWAY, Doptelet, ERLEADA, Empaveli, Enhertu, FOTIVDA, Gavreto, Hercessi, IBRANCE, IMBRUVICA, INJECTAFER, INQOVI, Itovebi, JAKAFI, JAYPIRCA, KEYTRUDA, LONSURF, LOQTORZI, LORBRENA, Lenvima, Lunsumio, MEKTOVI, MONOFERRIC, NERLYNX, NIKTIMVO, OCTAGAM IMMUNE GLOBULIN (HUMAN), OJJAARA, OPDIVO, Orserdu, POTELIGEO, PYRUKYND, Phesgo, Polivy, REBLOZYL, ROLVEDON, RYBREVANT, RYTELO, Rezlidhia, SARCLISA, SCEMBLIX, TAGRISSO, TALVEY, TAVALISSE, TECVAYLI, TUKYSA, Tecentriq Hybreza, Tibsovo, Trodelvy, ULTOMIRIS, VENCLEXTA, VERZENIO, VIVIMUSTA, Vanflyta, WAYRILZ, XPOVIO, Xtandi, Yescarta, ZYNLONTA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Braftovi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ARRAY BIOPHARMA INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error